Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
Christoph TauschKavitha KanesalingamStefanie HayozZoltan MatraiFlorian FitzalGuido HenkeDaniel R ZwahlenGünther GruberFrank ZimmermannMariacarla AndreozziMaite GoldschmidtAlexandra SchulzNadia MaggiRamon SaccilottoMartin HeidingerAndreas MuellerEkaterini Christina TampakiVesna Bjelic-RadisicÁkos SávoltViktor SmanykóDaniela HagenDieter J MüllerMichael GnantSibylle LoiblPagona MarkellouInga BekesDaniel EgleThomas RuhstallerSimone MuenstSherko KuemmelConny VrielingRok SatlerCharles BeccioliniSusanne BucherChristian KurzederColin SimonsonPeter M FehrNatalie GabrielRobert MarázDimitri SarlosKonstantin J DedesCornelia LeoGilles BerclazHisham FansaChristopher HagerKlaus ReisenbergerChristian F SingerGiacomo MontagnaRoland ReitsamerJelena WinklerGiang Thanh LamMathias K FehrTatiana NaydinaMagdalena KohlikKarine ClercValerijus OstapenkoLoïc LelièvreJörg HeilMichael KnauerWalter Paul WeberPublished in: Breast cancer research and treatment (2023)
Substantial heterogeneity in the use of NST with HR+/HER2-breast cancer exists in Europe. While stringent guidelines are available for its use in triple-negative and HER2+ breast cancer, there is a need for the development of and adherence to well-defined recommendations for HR+/HER2-breast cancer.